Literature DB >> 12668683

Regulation of the phosphatidylinositol 3-kinase, Akt/protein kinase B, FRAP/mammalian target of rapamycin, and ribosomal S6 kinase 1 signaling pathways by thyroid-stimulating hormone (TSH) and stimulating type TSH receptor antibodies in the thyroid gland.

Jae Mi Suh1, Jung Hun Song, Dong Wook Kim, Ho Kim, Hyo Kyun Chung, Jung Hwan Hwang, Jin Man Kim, Eun Suk Hwang, Jongkyeong Chung, Jeung-Hwan Han, Bo Youn Cho, Heung Kyu Ro, Minho Shong.   

Abstract

Thyroid-stimulating hormone (TSH) regulates the growth and differentiation of thyrocytes by activating the TSH receptor (TSHR). This study investigated the roles of the phosphatidylinositol 3-kinase (PI3K), PDK1, FRAP/mammalian target of rapamycin, and ribosomal S6 kinase 1 (S6K1) signaling mechanism by which TSH and the stimulating type TSHR antibodies regulate thyrocyte proliferation and the follicle activities in vitro and in vivo. The TSHR immunoprecipitates exhibited PI3K activity, which was higher in the cells treated with either TSH or 8-bromo-cAMP. TSH and cAMP increased the tyrosine phosphorylation of TSHR and the association between TSHR and the p85alpha regulatory subunit of PI3K. TSH induced a redistribution of PDK1 from the cytoplasm to the plasma membrane in the cells in a PI3K- and protein kinase A-dependent manner. TSH induced the PDK1-dependent phosphorylation of S6K1 but did not induce Akt/protein kinase B phosphorylation. The TSH-induced S6K1 phosphorylation was inhibited by a dominant negative p85alpha regulatory subunit or by the PI3K inhibitors wortmannin and LY294002. Rapamycin inhibited the phosphorylation of S6K1 in the cells treated with either TSH or 8-bromo-cAMP. The stimulating type TSHR antibodies from patients with Graves disease also induced S6K1 activation, whereas the blocking type TSHR antibodies from patients with primary myxedema inhibited TSH- but not the insulin-induced phosphorylation of S6K1. In addition, rapamycin treatment in vivo inhibited the TSH-stimulated thyroid follicle hyperplasia and follicle activity. These findings suggest an interaction between TSHR and PI3K, which is stimulated by TSH and cAMP and might involve the downstream S6K1 but not Akt/protein kinase B. This pathway may play a role in the TSH/stimulating type TSH receptor antibody-mediated thyrocyte proliferation in vitro and in the response to TSH in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12668683     DOI: 10.1074/jbc.M300805200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Identification of microRNAs that mediate thyroid cell growth induced by TSH.

Authors:  Takeshi Akama; Mariko Sue; Akira Kawashima; Huhehasi Wu; Kazunari Tanigawa; Sayuri Suzuki; Moyuru Hayashi; Aya Yoshihara; Yuko Ishido; Norihisa Ishii; Koichi Suzuki
Journal:  Mol Endocrinol       Date:  2012-02-02

2.  Fibroblasts expressing the thyrotropin receptor overarch thyroid and orbit in Graves' disease.

Authors:  Terry J Smith; Dolly A Padovani-Claudio; Ying Lu; Nupur Raychaudhuri; Roshini Fernando; Stephen Atkins; Erin F Gillespie; Andrew G Gianoukakis; Barbra S Miller; Paul G Gauger; Gerard M Doherty; Raymond S Douglas
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

Review 3.  The potential role of mTOR inhibitors in the treatment of endocrine tumors.

Authors:  S Grozinsky-Glasberg; I Shimon
Journal:  J Endocrinol Invest       Date:  2010-05-05       Impact factor: 4.256

4.  Prostaglandin E2 activates the mTORC1 pathway through an EP4/cAMP/PKA- and EP1/Ca2+-mediated mechanism in the human pancreatic carcinoma cell line PANC-1.

Authors:  Hui-Hua Chang; Steven H Young; James Sinnett-Smith; Caroline Ei Ne Chou; Aune Moro; Kathleen M Hertzer; Oscar Joe Hines; Enrique Rozengurt; Guido Eibl
Journal:  Am J Physiol Cell Physiol       Date:  2015-08-26       Impact factor: 4.249

5.  Involvement of mTOR in Type 2 CRF Receptor Inhibition of Insulin Signaling in Muscle Cells.

Authors:  Hongxia Chao; Haochen Li; Rebecca Grande; Vitor Lira; Zhen Yan; Thurl E Harris; Chien Li
Journal:  Mol Endocrinol       Date:  2015-04-15

6.  IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes.

Authors:  Michal Marzec; Xiaobin Liu; Monika Kasprzycka; Agnieszka Witkiewicz; Puthiyaveettil N Raghunath; Mouna El-Salem; Erle Robertson; Niels Odum; Mariusz A Wasik
Journal:  Blood       Date:  2007-11-19       Impact factor: 22.113

7.  Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.

Authors:  Roberta Malaguarnera; Kuen-Yuan Chen; Tae-Yong Kim; Jose M Dominguez; Francesca Voza; Bin Ouyang; Sushil K Vundavalli; Jeffrey A Knauf; James A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2014-07-16       Impact factor: 5.958

Review 8.  TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy.

Authors:  Terry J Smith
Journal:  Nat Rev Endocrinol       Date:  2015-01-06       Impact factor: 43.330

9.  Activation of mTORC1 signaling pathway in AIDS-related lymphomas.

Authors:  Mouna El-Salem; Puthiyaveettil N Raghunath; Michal Marzec; Xiaobin Liu; Monika Kasprzycka; Erle Robertson; Mariusz A Wasik
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

10.  Pentraxin-3 Is a TSH-Inducible Protein in Human Fibrocytes and Orbital Fibroblasts.

Authors:  Hao Wang; Stephen J Atkins; Roshini Fernando; Rui-Li Wei; Terry J Smith
Journal:  Endocrinology       Date:  2015-08-19       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.